Raltegravir Potassium
The potassium salt formulation of raltegravir used in combination with other antiretroviral drugs to suppress HIV replication and maintain immune function. It is well-tolerated and has a favorable drug interaction profile compared to some older HIV medications.
Moleküler Ağırlık
482,5000 g/mol
TPSA
153,00 Ų
Terapötik Alanlar
Etki Mekanizması
Inhibits viral integrase, preventing the insertion of viral DNA into the host cell genome and blocking viral replication.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits viral integrase, preventing the insertion of viral DNA into the host cell genome and blocking viral replication.
2D Yapı
Cite this structure
Embed this structure
SMILES
Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c([O-])c(=O)n2C)o1.[K+]
InChI
InChI=1S/C20H21FN6O5.K/c1-10-25-26-17(32-10)16(30)24-20(2,3)19-23-13(14(28)18(31)27(19)4)15(29)22-9-11-5-7-12(21)8-6-11;/h5-8,28H,9H2,1-4H3,(H,22,29)(H,24,30);/q;+1/p-1
Molecular Formula
C20H20FKN6O5
HBD / HBA
2 / 9
Döndürülebilir Bağlar
6
Ağır Atomlar
33
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
The potassium salt formulation of raltegravir used in combination with other antiretroviral drugs to suppress HIV replication and maintain immune function. It is well-tolerated and has a favorable drug interaction profile compared to some older HIV medications.
Inhibits viral integrase, preventing the insertion of viral DNA into the host cell genome and blocking viral replication.
Yes, Raltegravir Potassium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL518520. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 23668479. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="raltegravir-potassium"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/raltegravir-potassium/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/raltegravir-potassium/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/raltegravir-potassium/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="raltegravir-potassium"></drugfyi-drug>